|
Patent landscape, scope, and claims summary: |
Executive summary
US Patent 10,426,753 claims a “supramolecular combinatorial therapeutic” (SCT) built around a taxane-lipid conjugate in which the taxane-lipid conjugate is a cabazitaxel-lipid conjugate (claims 1-13), and separately claims a second taxane-lipid SCT around paclitaxel and docetaxel (claim 14). The core exclusivity risk in practice is not the SCT format alone, but the breadth of the taxane-lipid conjugate selection set (cabazitaxel conjugates 1-15 and 21-32), plus the downstream cover provided by wide carrier and excipient language (liposomes, micelles, emulsions, particles; 1–99% w/w lipid; long lists of lipids, PEG-lipids, targeting ligands, and PI3K inhibitors). The resulting landscape is likely to be dominated by: (i) prior art on taxane-lipid conjugates (cabazitaxel/paclitaxel/docetaxel), (ii) prior art on co-delivery SCT-like liposomal nanomedicine stacks combining taxanes with PI3K and/or platinum and/or antibodies (notably checkpoint inhibitors), and (iii) formulation and use claims already prosecuted and litigated in taxane nanocarriers and combination immuno-oncology regimens.
US Patent 10,426,753 claims scope and what the protected SCT actually covers
US 10,426,753 is structured as a platform-style claim set with (a) a defining conjugate, (b) an imposed carrier class, and (c) an expansive optional “combinatorial” payload layer.
Claim 1 anchor: cabazitaxel-lipid conjugate in a supramolecular combinatorial therapeutic
- What is required: an SCT comprising a taxane-lipid conjugate where the taxane-lipid conjugate is a cabazitaxel-lipid conjugate.
- Which conjugates are within scope: cabazitaxel-lipid conjugates selected from conjugates 1–15 and 21–32 (the patent’s own structure set referenced as ##STR00048## through ##STR00057##).
- What is not required: no explicit requirement for PEG, targeting ligand, PI3K inhibitor, platinum, or antibody in claim 1 (those appear in dependent claims).
Practical read-through: if a competitor’s SCT uses a cabazitaxel-lipid conjugate outside that enumerated set, it can attempt to design around the claim even if the rest of the formulation is the same.
Claim 2: carrier form and lipid mass fraction
- Carrier formats explicitly covered: liposome, emulsion, micelle, or particle.
- Lipid content range: SCT comprises ~1% to ~99% (w/w) of the taxane conjugate.
Practical read-through: this claim covers a wide set of nanoformulation operating envelopes. It is broad enough that minor differences in payload ratio may not avoid infringement if the taxane conjugate mass fraction still falls in the range.
Claim 3: combinatorial payload list (PI3K inhibitor, platinum, antibody, and an immuno-oncology panel)
Claim 3 adds multiple optional payload layers, each framed as “further comprises,” with an antibody and checkpoint subset:
- Optional co-contents:
- lipid-conjugated PI3K inhibitor
- lipid-conjugated platinum compound
- lipid-conjugated antibody
- plus broad lipid excipients (neutral, cationic, anionic, amphiphilic) and sterols and programmable fusion lipids
- plus “pharmaceutically acceptable carrier”
- Antibody limitations: antibody can be therapeutic, targeting ligand, or immunomodulatory including anti-PD-1 and anti-PD-L1 (and combinations).
- PI3K inhibitor conjugate selection: PI3K inhibitor conjugate defined as ##STR00058## and the payload is present either ~1–99% (w/w) of PI3K conjugate or platinum conjugate or antibody conjugate (as written).
- Molar ratio between taxane conjugate and PI3K/platinum/antibody conjugate: ~10:1 to ~1:10.
Practical read-through: claim 3 is expansive and “stacked.” A product does not need all three payload classes simultaneously; it can fall into the claim by using taxane conjugate + one of PI3K/platinum/antibody conjugates plus the specified lipid architecture plus broad lipid/PEG options introduced across other dependent claims.
Claim 4: further excipient architecture (PEG, targeting ligand) and large chemotherapeutic menu
- Requires: further comprises at least one additional lipid and may comprise PEG and a targeting ligand and/or a chemotherapeutic agent.
- Additional lipid definition: “at least one additional lipid is a phospholipid,” with an extremely broad list.
- PEG architecture: PEG conjugated with the SCT component or PEG conjugated to a lipid; PEG-conjugated lipid is selected from categories including DSPE-PEG2000.
- Targeting ligand: extremely broad list including antibody formats, fragments, peptides, proteins, glycoproteins, receptors, etc., with a binding requirement to cancer markers/receptors.
- Chemotherapeutic agent: a very large list including most standard oncologics and many targeted agents, plus it again cross-references PI3K inhibitor options.
Practical read-through: claim 4 is less about a single payload and more about capturing conventional “stealth + targeting + multi-lipid” nanomedicine architecture.
Claim 5: narrow preferred composition ratios (phosphatidylcholine + DSPE-PEG2000 + specific phospholipid subset)
Claim 5 adds specific composition constraints:
- At least one taxane-lipid conjugate combined with one or more of: PI3K-lipid conjugate, platinum-lipid conjugate, antibody-lipid conjugate.
- Includes PEG conjugated lipid and a phospholipid.
- Molar ratios: taxane-lipid conjugate : phospholipid : PEG-lipid is about 10–0.1 : 10–0.1 : 10–0.01 (as written).
- PEG-lipid: DSPE-PEG2000
- Phospholipid: phosphatidylcholine selected from SOPC, POPC, Egg PC, HSPC.
Practical read-through: this dependent claim is narrower than claims 1-4. A product that avoids DSPE-PEG2000 and avoids that specific PC subset can reduce exposure to claim 5 but may still land in claims 1-4 or 6-13.
Claim 6: particle size range
- Nanoparticle diameter: ~5 nm to ~500 nm.
Claims 7-8 and 12-13: methods of treating cancer
- Method claims cover administering the SCT and optionally co-administering other therapies.
- Cancer types listed: breast, ovarian, glioma, gastrointestinal, prostate, and many others; duplicates exist across claims.
- Immunomodulators: NK cells, cytokine-activated killer cells, cytotoxic T cells, dendritic cells, plus anti-PD-L1/anti-PD-1 and a list of other immunotherapies.
Practical read-through: infringement risk for method claims tracks where there is a clear clinical regimen label. If a product is marketed for multiple tumor types and combinations, method claims are harder to avoid.
Claim 14: paclitaxel-docetaxel SCT parallel
Claim 14 introduces additional SCT variants:
- taxane-lipid conjugate is paclitaxel-lipid selected from conjugates 16-17
- docetaxel-lipid selected from conjugates 18-20 and 33
Practical read-through: claim 14 indicates the patent is a family-like disclosure for multiple taxanes. Even if the asserted case focuses on cabazitaxel (claims 1-13), the existence of claim 14 increases the chance that related patents or related continuation claims exist for paclitaxel/docetaxel versions.
How broad are the key design-around levers: conjugate set, PEG/lipid choices, ratios, and carrier form?
The landscape is best evaluated as claim-element “gates” that map to practical formulation choices.
Gate 1: cabazitaxel-lipid conjugate enumeration
- The claim is tethered to cabazitaxel-lipid conjugates 1–15 and 21–32.
- If a competitor’s cabazitaxel-lipid conjugate is structurally different and outside those enumerations, it creates a path to avoid claims 1-13 even if the product uses the same carrier and co-payload approach.
Gate 2: carrier class
- If the product is not a liposome/emulsion/micelle/particle under the patent’s interpretation, that is a potential evasion point.
- In practice, most nanocarriers used in oncology fall into these categories, so this is often not a strong design-around gate.
Gate 3: lipid mass fraction and molar ratio
- The patent ranges are broad: 1–99% (w/w) taxane conjugate and molar ratios as wide as 10:1 to 1:10.
- If the competitor aligns with “typical” lipid-nanomedicine formulations, it likely still meets broad ranges.
Gate 4: the optional payload that triggers claim 3
- Claim 3 requires additional lipid-conjugated PI3K inhibitor and/or platinum and/or antibody; it does not require all of them.
- That means a competitor can still infringe if it includes just one lipid-conjugated payload class in the taxane SCT framework.
Gate 5: DSPE-PEG2000 and specific PC subset
- Narrower in claim 5, but broad in other dependent claims.
- If avoided, it primarily reduces coverage under claim 5 and parts of claim 11.
What patents protect cabazitaxel-lipid conjugates and SCT co-delivery in the US
A comprehensive analysis requires the actual patent family context and prosecution history around US 10,426,753, including citations and claim amendments. Without that dataset, only claim-driven inference is possible from the language you provided.
Likely dominant prior-art clusters that would attack novelty and nonobviousness
-
Taxane-lipid conjugates (cabazitaxel/paclitaxel/docetaxel)
- Field: lipid prodrug conjugates, amphiphilic taxanes, and lipid-anchored taxane formulations to modify solubility and pharmacokinetics.
- Typical overlap: conjugate-by-lipid linkers, amphiphilic design, and nanoparticle assembly.
-
Lipid nanocarriers with PEG and targeting
- Field: stealth PEGylated liposomes/micelles, targeting ligands (peptides/antibodies), and standard phospholipid recipes like DSPE-PEG2000 and PC variants (POPC/SOPC/HSPC/EPC).
-
Combination oncology in nanocarriers
- Field: co-delivery of cytotoxics with targeted pathway inhibitors (including PI3K axis inhibitors) and/or platinum agents.
- Typical overlap: liposome or polymer/lipid nanoparticles co-encapsulating or co-localizing taxane + kinase inhibitor or platinum + immunotherapy.
-
Checkpoint immunotherapy with liposomal co-delivery
- Field: incorporation of anti-PD-1/PD-L1 antibodies and or immunomodulatory agents into therapeutic platforms.
- Typical overlap: antibodies as conjugates or co-administered immunomodulators in combination therapy regimens.
Where the patent likely gains strength
- The most defensible element is the specific enumerated cabazitaxel-lipid conjugate structures (conjugates 1–15 and 21–32) and the patent’s specific “SCT” definition tying taxane-lipid conjugates to the enumerated payload architecture.
- The most vulnerable elements are the broad “comprising” and list-based features that can overlap with common prior art recipes (PEGylated PC liposomes, standard lipid excipients, broad list of PI3K inhibitors, broad list of chemotherapeutics, broad targeting ligand definitions).
How many potential infringement scenarios exist for products using cabazitaxel lipid conjugates
Based on your claim set, infringement scenarios typically fall into a small number of buckets.
Scenario A: cabazitaxel-lipid conjugate in SCT carrier, no lipid-conjugated PI3K/platinum/antibody
- Covers claims 1, 2, 6, and compositions/methods that do not require the extra payload.
- Most exposure depends on whether the product’s conjugate matches enumerated conjugates.
Scenario B: cabazitaxel-lipid SCT + lipid-conjugated PI3K inhibitor conjugate
- Adds claim 3 and potentially claim 11 (depending on PEG/lipid selections).
- Molar ratio and payload range are broad, which increases risk.
Scenario C: cabazitaxel-lipid SCT + lipid-conjugated platinum
- Similar exposure to scenario B.
Scenario D: cabazitaxel-lipid SCT + lipid-conjugated antibody (anti-PD-1/PD-L1)
- Adds claim 3 and method claims 7-8 and 12-13 if used as described in indications and regimens.
Scenario E: only combination via co-administration (not part of the SCT)
- The patent’s method claims cover co-administration of additional therapies, but actual infringement depends on how the SCT is administered and what is “optionally co-administering” per the claim scope.
Exclusivity and patent term: when does US 10,426,753 lose protection?
Not enough information is provided here to compute:
- the exact filing date,
- any nonprovisional priority date(s),
- patent term adjustments (PTA),
- any terminal disclaimers,
- whether the patent is eligible for patent term extension (PTE) under 35 USC 156.
Without those data, a correct exclusivity timeline cannot be stated.
Orange Book status: is US 10,426,753 listed for cabazitaxel products?
No US FDA Orange Book listing data is provided. Orange Book status depends on:
- the specific marketed drug product name,
- active ingredient identity,
- NDA/BLA scope,
- and patent list decisions by the NDA/BLA holder(s).
No definitive answer can be produced from the claim text alone.
Patent litigation and Paragraph IV challenge risk
No litigation docket, settlement, or Paragraph IV case identifiers are provided. A complete analysis requires:
- litigated parties,
- asserted claims,
- venue,
- ANDA product(s),
- and court construction outcomes.
No definitive “who is challenging whom” mapping can be produced from the claim language alone.
How does US 10,426,753 compare with typical taxane nanoformulation IP estates?
Compared with common taxane nanomedicine estates, US 10,426,753 is:
- claim-broad on carrier and excipient architecture (liposome/micelle/emulsion/particle; 1–99% lipid; extensive lipid/PEG lists),
- payload-accordion style via “further comprises” (PI3K inhibitor, platinum, antibody; checkpoint antibodies enumerated),
- and anchored by specific cabazitaxel-lipid conjugate enumeration, which is the main “hard” tether.
In litigation, this structure usually creates:
- strong defense arguments around “specific conjugate structures” matching the enumerated claim set,
- and strong invalidity arguments around the general SCT architecture being an aggregation of known nanocarrier and combination-therapy concepts, unless the enumerated conjugates are sufficiently novel over the cited prior art.
Commercial and regulatory implications: what generic and biosimilar risk exists?
- For small-molecule combination nanomedicines: “generic” risk is typically ANDA-to-505(j) only if an ANDA route exists for the product and if it is considered a “drug product” eligible for generic approval. For novel nanoformulations, regulatory pathways depend on whether the active ingredient is treated as a small molecule vs complex biologic-like composition.
- For antibody components (anti-PD-1/PD-L1): if the SCT includes lipid-conjugated antibodies, biosimilar relevance depends on whether any antibody is already a known biologic with biosimilar pathways and whether the antibody in the product is identical to an approved biologic.
Because no active product, NDA/BLA number, or drug identity is provided, the regulatory and commercial risk profile cannot be tied to a specific FDA entry.
Key Takeaways
- US 10,426,753 is a broad SCT platform claim anchored to cabazitaxel-lipid conjugates explicitly enumerated as conjugates 1–15 and 21–32.
- The claims then expand coverage across nano-carriers (liposome/emulsion/micelle/particle) and wide lipid mass and molar ratios, which reduces the value of ratio-based design-around.
- The patent’s most consequential design-around lever is whether the competing cabazitaxel-lipid conjugate is structurally outside the enumerated set.
- Secondary design-around levers (PEGylation type, specific phosphatidylcholine subset, nanoparticle diameter) mostly affect dependent claim coverage rather than the base SCT definition.
- A complete “critical analysis” of litigation strength, exclusivity timeline, Orange Book status, and challenge risk cannot be completed from claim text alone.
FAQs
-
What element of US 10,426,753 is the hardest to design around?
The specificity of the enumerated cabazitaxel-lipid conjugate structures (1–15 and 21–32).
-
Do the claims require PI3K/platinum/antibody simultaneously?
No. Claim 3 is written so the SCT “further comprises” one or more of those lipid-conjugated payload types.
-
Can avoiding DSPE-PEG2000 eliminate infringement risk?
It narrows coverage under dependent claims that specify DSPE-PEG2000, but it does not eliminate exposure to broader claims that do not require that specific PEG-lipid.
-
Does claim 6 create a strong formulation design-around based on size?
It creates a window of 5–500 nm for dependent claim 6, but base claims 1-5 and related dependent claims may still apply if the carrier is within other covered categories.
-
Is claim 14 a separate taxane family within the same patent?
Yes. Claim 14 covers SCT variants using paclitaxel-lipid conjugates (16–17) and docetaxel-lipid conjugates (18–20 and 33).
References
- US Patent 10,426,753 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
